Affordable Access

Access to the full text

Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients

Authors
  • montalbán-hernández, karla
  • cantero-cid, ramón
  • lozano-rodríguez, roberto
  • pascual-iglesias, alejandro
  • avendaño-ortiz, josé
  • casalvilla-dueñas, josé carlos
  • bonel pérez, gloria cristina
  • guevara, jenny
  • marcano, cristóbal
  • barragán, cristina
  • valentín, jaime
  • del fresno, carlos
  • aguirre, luis augusto
  • collazo, eduardo lópez
Publication Date
Aug 02, 2021
Identifiers
DOI: 10.3390/cancers13153896
OAI: oai:mdpi.com:/2072-6694/13/15/3896/
Source
MDPI
Keywords
Language
English
License
Green
External links

Abstract

Colorectal cancer (CRC) is the second most deadly and third most commonly diagnosed cancer worldwide. There is significant heterogeneity among patients with CRC, which hinders the search for a standard approach for the detection of this disease. Therefore, the identification of robust prognostic markers for patients with CRC represents an urgent clinical need. In search of such biomarkers, a total of 114 patients with colorectal cancer and 67 healthy participants were studied. Soluble SIGLEC5 (sSIGLEC5) levels were higher in plasma from patients with CRC compared with healthy volunteers. Additionally, sSIGLEC5 levels were higher in exitus than in survivors, and the receiver operating characteristic curve analysis revealed sSIGLEC5 to be an exitus predictor (area under the curve 0.853 / cut-off &gt / 412.6 ng/mL) in these patients. A Kaplan–Meier analysis showed that patients with high levels of sSIGLEC5 had significantly shorter overall survival (hazard ratio 15.68 / 95% CI 4.571–53.81 / p ≤ 0.0001) than those with lower sSIGLEC5 levels. Our study suggests that sSIGLEC5 is a soluble prognosis marker and exitus predictor in CRC.

Report this publication

Statistics

Seen <100 times